Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncoy platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the submission of three patents to the European Patent Office. This underscores Medigene’s commitment to advancing T cell-based immunotherapies for the treatment of solid tumors.
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
